Compare ADMA Biologics Inc (ADMA) vs Workiva Inc (WK) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Workiva (WK) trades at $51.54, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $0.77, beating estimates, and shows improving revenue trends. Cash flow from operations grew to $140.07M in 2025, with net income turning positive in 2026 projections. Recent news highlights AI adoption in finance and upcoming Q2 2026 earnings.

Outlook remains positive with a consensus price target of $71.00, implying 38% upside, supported by 16 buy ratings. Risks include high valuation multiples (P/E 214.75) and reliance on sustained earnings growth. The stock presents a growth opportunity if execution continues, but volatility near resistance at $52 warrants monitoring.